NeuroPace (NPCE) Competitors

Cadre (NYSE:CDRE) and NeuroPace (NASDAQ:NPCE) are both small-cap industrial products companies, but which is the superior business? We will compare the two companies based on the strength of their risk, media sentiment, community ranking, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

Do analysts prefer CDRE or NPCE?

Cadre presently has a consensus price target of $39.67, indicating a potential upside of 17.76%. NeuroPace has a consensus price target of $14.80, indicating a potential upside of 7.48%. Given Cadre's higher possible upside, equities analysts clearly believe Cadre is more favorable than NeuroPace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cadre	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
NeuroPace	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80

Do insiders and institutionals have more ownership in CDRE or NPCE?

44.0% of Cadre shares are owned by institutional investors. Comparatively, 78.8% of NeuroPace shares are owned by institutional investors. 37.0% of Cadre shares are owned by company insiders. Comparatively, 22.2% of NeuroPace shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Is CDRE or NPCE more profitable?

Cadre has a net margin of 6.34% compared to NeuroPace's net margin of -36.74%. Cadre's return on equity of 12.88% beat NeuroPace's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cadre	6.34%	12.88%	6.06%
NeuroPace	-36.74%	-205.41%	-28.29%

Does the MarketBeat Community favor CDRE or NPCE?

NeuroPace received 14 more outperform votes than Cadre when rated by MarketBeat users. Likewise, 60.00% of users gave NeuroPace an outperform vote while only 55.17% of users gave Cadre an outperform vote.

Company	Underperform	Outperform
Cadre	Outperform Votes 16 55.17%	Underperform Votes 13 44.83%
NeuroPace	Outperform Votes 30 60.00%	Underperform Votes 20 40.00%

Does the media favor CDRE or NPCE?

In the previous week, NeuroPace had 8 more articles in the media than Cadre. MarketBeat recorded 10 mentions for NeuroPace and 2 mentions for Cadre. Cadre's average media sentiment score of 0.70 beat NeuroPace's score of 0.51 indicating that Cadre is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cadre	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NeuroPace	4 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has better earnings and valuation, CDRE or NPCE?

Cadre has higher revenue and earnings than NeuroPace. NeuroPace is trading at a lower price-to-earnings ratio than Cadre, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cadre	$516.16M	2.65	$38.64M	$0.83	40.58
NeuroPace	$65.42M	6.28	-$32.96M	-$1.00	-13.77

Which has more risk and volatility, CDRE or NPCE?

Cadre has a beta of 1.27, indicating that its share price is 27% more volatile than the S&P 500. Comparatively, NeuroPace has a beta of 2.05, indicating that its share price is 105% more volatile than the S&P 500.

Summary

Cadre beats NeuroPace on 10 of the 18 factors compared between the two stocks.